On September 13, 2021 Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, reported that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma will present at the H.C. Wainwright 23rd Annual Global Investment Conference (Press release, Benitec Biopharma, SEP 13, 2021, https://www.prnewswire.com/news-releases/benitec-biopharma-to-present-at-hc-wainwrights-23rd-annual-global-investment-conference-301375670.html [SID1234587641]). The relevant details are outlined below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date:

Wednesday, September 13, 2021

Event:

H.C. Wainwright 23rd Annual Global Investment Conference

Time:

7:00 P.M. ET

Link:

www.hcwevents.com

Please visit the link above to register for the presentation which will be presented via webcast during the virtual conference. The September 2021 Corporate Presentation is also viewable on the Investor Relations section of the Company’s website, here: View Source

If you are an institutional investor, and would like to attend the Company’s presentation, click on the following link (www.hcwevents.com) to register. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.